DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016" report to their offering.
Glioblastoma Multiforme (GBM) pipeline therapeutics constitutes close to 356 molecules, out of which approximately 303 molecules are developed by Companies and the remaining by Universities/Institutes. Our latest report 'Glioblastoma Multiforme - Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glioblastoma Multiforme (GBM) Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes.
Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy. The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 81, 45, 5, 141, 19 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 11, 28 and 7 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects.
Companies Mentioned - Partial List
- AbbVie Inc.
- Activartis Biotech GmbH
- Aduro BioTech, Inc.
- Advanced Accelerator Applications S.A.
- Advanced Cancer Therapeutics
- Advantagene, Inc.
- Advenchen Laboratories, LLC
- Affimed GmbH
- Agenus, Inc.
- Amal Therapeutics SA
- Ambrx, Inc.
- Amgen Inc.
- Ampio Pharmaceuticals, Inc.
- AngioChem Inc.
- APIM Therapeutics AS
- Apogenix GmbH
- Ariad Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Axelar AB
- Basilea Pharmaceutica AG
- Batu Biologics, Inc.
- BeiGene, Ltd.
- Bexion Pharmaceuticals, LLC.
- Bioasis Technologies Inc.
- BioCancell Ltd
- Biomar Microbial Technologies
- Bioncotech Therapeutics S.L.
- Biovista Inc.
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- BTG Plc
- CalAsia Pharmaceuticals, Inc.
- Cantex Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/vbtx3k/glioblastoma
